Blog
RSS FeedPosted by Michael Wonder on 17 Aug 2021
Will Government further expand reimbursement for rare leukaemia drugs?
17 August 2021 - As the Government has gradually increased reimbursement for combination drugs treating chronic lymphocytic leukaemia, patients’ hopes ...
Posted by Michael Wonder on 10 Aug 2021
Companion diagnostics are growing rapidly worldwide. What about in Korea?
10 August 2021 - The global companion diagnostics market is expanding fast, but Korea has yet to develop related technologies, ...
Posted by Michael Wonder on 02 Aug 2021
Novartis’ psoriatic arthritis drug to get expanded reimbursement
2 August 2021 - Novartis Korea said Monday its interleukin-17a inhibitor Cosentyx (secukinumab) began receiving reimbursement as a first-line biologics ...
Posted by Michael Wonder on 28 Jul 2021
'New regulation limiting generic drugs will change industrial paradigm'
27 July 2021 - The Korea Pharmaceutical and Bio-pharma Manufacturers Association said the revision of the Pharmaceutical Affairs Act to ...
Posted by Michael Wonder on 12 Jul 2021
‘MSD Korea proposed unprecedented offer for Keytruda reimbursement’
12 July 2021 - MSD’s Keytruda (pembrolizumab), immunotherapy for lung cancer, is the company’s flagship item that sold $14.38 billion ...
Posted by Michael Wonder on 12 Jul 2021
Leukaemia patients demand reimbursement for Novartis’ Kymriah
12 July 2021 - Korean leukaemia patients have urged the government to provide rapid reimbursement of Kymriah, the first CAR-T ...
Posted by Michael Wonder on 11 Jul 2021
Novartis Korea to continue discussing reimbursement plan for SMA drug Zolgensma
9 July 2021 - Novartis said Friday that it would continue to discuss with the domestic regulators to receive reimbursement ...
Posted by Michael Wonder on 07 Jul 2021
Innovative health technologies need special subsidy
7 July 2021 - Developing innovative health technologies is very important because they can extend human life by broadening the ...
Posted by Michael Wonder on 30 Jun 2021
Sanofi’s Praluent provides solution for Korean dyslipidaemia patients
30 June 2021 - Sanofi Aventis is strengthening its position in the local dyslipidaemia treatment market with Praluent (alirocumab), a ...
Posted by Michael Wonder on 22 Jun 2021
HIRA gives Leclaza benefits easily but delays decision on Tagrisso
22 June 2021 - Yuhan's Leclaza (lazertinib), a third-generation treatment for EGFR mutated non-small cell lung cancer, has won the ...
Posted by Michael Wonder on 10 Jun 2021
Yuhan's Leclaza to be cheaper than AstraZeneca's Tagrisso
10 June 2021 - The price of Yuhan's third generation epidermal growth factor receptor tyrosine kinase inhibitor for treating patients ...
Posted by Michael Wonder on 27 May 2021
'Anticancer drug should extend life for 22 months to get insurance benefits'
27 May 2021 - A research team at National Cancer Center has found that the public believes that for an ...
Posted by Michael Wonder on 27 May 2021
7 out of 10 Koreans want cheaper drug with same ingredient
27 May 2021 - Seven out of 10 Koreans want to lower the drug cost by choosing a cheaper generic ...
Posted by Michael Wonder on 24 May 2021
Why is Tagrisso not reimbursable as first-line treatment in Korea?
24 May 2021 - Osimertinib (Tagrisso) has transformed the treatment paradigm for epidermal growth factor receptor mutation positive non-small cell ...
Posted by Michael Wonder on 19 May 2021
‘Use effective drugs in early multiple myeloma to prevent relapse’
19 May 2021 - Multiple myeloma patients suffer frequent recurrences, and treatment response rates and response durations plummet along with ...